Triptorelin is a decapeptide that acts as a gondatropin releasing hormone antagonist or GnRH. This is used as part of a pamoate salt or acetate chemical program. Applying triptorelin to an animal test subject will cause a constant stimulation of their pituitary gland which will then decrease the secretion of gonadotropin lutenizing hormone secretions as well as the secretion of follicle stimulating hormone. Triptorelin is similar to other GnRH antagonists because it is being tested for its potential use in managing hormone-responsive cancers such as breast or prostate cancer. Triptorelin is also being researched for its potential use in helping to correct conditions such as precocious puberty or estrogen dependent diseases like uterine fibroids. It may also be helpful in assisting with reproduction, though research on these subjects is currently inconclusive.
Potential Uses for Disease Management
The reaction that triptorelin can instill with different hormones is being researched for its potential use in helping to manage hormone-responsive diseases. Triptorelin is being widely researched for its potential use in managing prostate cancer. When this chemical is applied to animals that have this cancer it can cause a testosterone surge that will raise the initial up level of the animal’s testosterone levels. This is referred to as a flare effect. In male animals reducing serum testosterone levels into a range that is considered normal after a surgical castration can occur around 2-4 weeks of the animal consistently being exposed to triptorelin. By contrast gondatropin releasing hormone antagonists will not cause this testosterone surge when they are applied or animals. Instead, these chemicals will cause a sudden and dramatic reduction of testosterone levels. The full uses of triptorelin for controlling testosterone levels are still being researched. This research is not yet ready to confirm any sort of result that it could have on male human test subjects. As results continue to be published, researchers are better learning the levels of triptorelin that could be used to create the proper testosterone levels, to manage prostate cancer in animals.
Protective Effects of the on Ovarian Gonadotoxicity
In order to demonstrate the potential protective effects GnRH forms like triptorelin could have, a study was conducted on the gonadotoxicity of chemotherapy-induced ovarian levels. During this study, twenty-four female mice that were virgins yet sexually mature were divided into four testing groups. The first received applications of busulfan, the second a low application of triptorelin along with busulfan, the third a high application of triptorelin and busulfan and a final control group. The mice in the low and high triptorelin application group were provided with injections of 3.8 and 38mg/kg of triptorelin which was administered subcutaneously. Four weeks into the study the low and high triptorelin groups were injected intraperitoneally with 36mg/kg administrations of busulfan. Four weeks after these histologic examinations were performed to determine the results of these applications. There was an obvious destruction of the structure of the ovaries following the chemical administrations which was coupled with a depletion of the primary, primordial and secondary follicles. This was most demonstrated in group B when comparing these mice to those of the control group. In spite of this indication there was not much of a statistical significance in the differences amongst the groups. The group which received high applications of triptorelin with bulsulfan saw a significantly larger effect on the primary and primordial follicles when compared to the low triptorelin group which demonstrates the potential of triptorelin to be used as a pre-treatment in ovarian protection, though additional study will be needed to fully explore these effects. The results of this study note an application-dependent protective effect of triptorelin in animals from gonadotoxic chemotherapy, allowing this chemical to act as a GnRH form of an ovarian reserve which suggests that GnRH forms could be used to preserve fertility during these treatments. Triptorelin is typically sold to researchers under the names gonapeptyl, decapeptyl and diphereline from worldwide retailers. Manufacturers such as Watson will typically sell triptorelin under the name Trelstar. The chemical is also sold out of Iran under the name Variopeptyl, though this formula is not as widely sold to worldwide research hubs. Those that are hoping to replicate very specific results in their research with triptorelin can contact specific manufacturers worldwide to ensure that the manufacturing process used will not impact the consistency of your trials.
Resource Box: http://en.wikipedia.org/wiki/Triptorelin